Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells $526,800.00 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert Blum sold 7,500 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $70.24, for a total value of $526,800.00. Following the completion of the transaction, the chief executive officer owned 377,820 shares of the company’s stock, valued at $26,538,076.80. The trade was a 1.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics Stock Up 0.7%

NASDAQ:CYTK opened at $71.93 on Thursday. Cytokinetics, Incorporated has a 52 week low of $47.22 and a 52 week high of $88.31. The stock’s fifty day moving average is $79.60 and its two-hundred day moving average is $72.41. The company has a market capitalization of $8.95 billion, a P/E ratio of -9.96 and a beta of 0.36.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.63) by $0.13. The business had revenue of $28.62 million for the quarter, compared to analysts’ expectations of $17.59 million. The business’s revenue for the quarter was down 57.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.12) earnings per share. Sell-side analysts anticipate that Cytokinetics, Incorporated will post -6 earnings per share for the current fiscal year.

Institutional Trading of Cytokinetics

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Cytokinetics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company’s stock valued at $765,538,000 after purchasing an additional 191,336 shares during the period. California State Teachers Retirement System increased its holdings in Cytokinetics by 7,880.8% during the 2nd quarter. California State Teachers Retirement System now owns 10,901,679 shares of the biopharmaceutical company’s stock worth $928,714,000 after purchasing an additional 10,765,080 shares during the period. State Street Corp raised its position in Cytokinetics by 3.7% in the 4th quarter. State Street Corp now owns 5,825,295 shares of the biopharmaceutical company’s stock valued at $370,139,000 after purchasing an additional 207,961 shares in the last quarter. Deep Track Capital LP boosted its stake in shares of Cytokinetics by 17.8% in the 3rd quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock valued at $236,328,000 after buying an additional 650,000 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Cytokinetics by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 3,056,017 shares of the biopharmaceutical company’s stock valued at $194,214,000 after buying an additional 15,815 shares during the period.

Analyst Upgrades and Downgrades

A number of research analysts have commented on CYTK shares. Wall Street Zen cut Cytokinetics from a “hold” rating to a “sell” rating in a research note on Saturday, August 29th. Needham & Company LLC increased their target price on Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. HC Wainwright restated a “buy” rating and set a $140.00 target price on shares of Cytokinetics in a report on Monday. Truist Financial lifted their target price on Cytokinetics from $106.00 to $112.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Finally, Wells Fargo & Company lifted their target price on Cytokinetics from $95.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Eighteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $103.37.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: New Phase 3 progress in non-obstructive hypertrophic cardiomyopathy (HCM) expands aficamten’s potential market beyond obstructive HCM. Additional study findings also suggest benefits across both forms of the disease, strengthening the outlook for Cytokinetics’ lead cardiovascular program. Cytokinetics Reaches a Phase 3 First in Non-Obstructive HCM Can CYTK’s Aficamten Strengthen Its HCM Growth Prospects?
• Positive Sentiment: Evercore ISI and Goldman Sachs reaffirmed their Buy ratings on CYTK, while HC Wainwright also maintained its Buy recommendation. The repeated endorsements reinforce the favorable sell-side view of Cytokinetics’ pipeline and commercial potential. Evercore ISI Remains a Buy on Cytokinetics Goldman Sachs Reaffirms Its Buy Rating on Cytokinetics
• Neutral Sentiment: Management will participate in a Citi BioPharma investor conference on September 9. The event could provide pipeline or regulatory updates, but the announcement itself contained no new financial or clinical data. Cytokinetics to Participate in September Investor Conferences
• Negative Sentiment: CEO Robert Blum sold 7,500 shares for approximately $526,800, and director B. Lynne Parshall sold 5,000 shares for about $357,400. Both transactions were made under pre-arranged Rule 10b5-1 plans, which reduces their usefulness as signals of current management sentiment, but the sales may weigh modestly on investor confidence.
• Negative Sentiment: Cytokinetics remains unprofitable, with analysts expecting a substantial full-year loss. Its latest quarterly revenue also declined year over year, leaving the stock dependent on clinical and regulatory execution rather than current earnings.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.